Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group

Patrick M. Forde, Phil Bonomi, Alice Shaw, Gideon M. Blumenthal, Andrea Ferris, Chirag Patel, Allen Melemed, Upal Basu Roy, Anuradha Ramamoorthy, Qi Liu, Timothy Burns, Justin F. Gainor, Christine Lovly, Zofia Piotrowska, Jonathan Lehman, Wendy Selig

Research output: Contribution to journalComment/debatepeer-review

Abstract

Low rates of adult patient participation have been a persistent problem in cancer clinical trials and have continued to be a barrier to efficient drug development. The routine use of significant exclusion criteria has contributed to this problem by limiting participation in studies and creating significant clinical differences between the study cohorts and the real-world cancer patient populations. These routine exclusions also unnecessarily restrict opportunities for many patients to access potentially promising new therapies during clinical development. Multiple efforts are underway to broaden eligibility criteria, allowing more patients to enroll in studies and generating more robust data regarding the effect of novel therapies in the population at large. Focusing specifically on lung cancer as an example, a multistakeholder working group empaneled by the LUNGevity Foundation identified 14 restrictive and potentially outdated exclusion criteria that appear frequently in lung cancer clinical trials. As a part of the project, the group evaluated data from multiple recent lung cancer studies to ascertain the extent to which these 14 criteria appeared in study protocols and played a role in excluding patients (screen failures). The present report describes the working group's efforts to limit the use of these routine exclusions and presents clinical justifications for reducing the use of 14 criteria as routine exclusions in lung cancer studies, potentially expanding trial eligibility and improving the generalizability of the results from lung cancer trials.

Original languageEnglish (US)
Pages (from-to)295-307
Number of pages13
JournalClinical lung cancer
Volume21
Issue number4
DOIs
StatePublished - Jul 2020

Keywords

  • Cancer clinical trials
  • Eligibility criteria
  • Expanded access
  • Non–small-cell lung cancer
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group'. Together they form a unique fingerprint.

Cite this